Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Chao Liu, Hong Lu, Fei Yuan, Wei-Li Chen, Hong-Rong Xu, Hui Li, Cheng-Pang Hsu, Ogo Egbuna, Jihua Wu, Clapton Dias, Bassam Abosaleem, Jitesh Rana, Maria Laura Monsalvo, Xue-Ning Li & Zhigang Yu. (2019) A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects. Clinical Pharmacology: Advances and Applications 11, pages 145-153.
Read now
Read now
Articles from other publishers (17)
Xue-Ning Li, Hong-Rong Xu, Ellen Cui, Kamilla Buchberg Petersen, Janka Ryding, Anders Ettrup, Jette Buch Østergaard & Frank Larsen. (2023) Pharmacokinetics and Safety of Eptinezumab in Healthy Chinese Participants: A Randomized Clinical Trial. Clinical Drug Investigation 43:11, pages 873-881.
Crossref
Crossref
Miwa Haranaka, Takanori Tanaka, SungHyun Kim, YunJu Bae, DaBee Jeon, EunJin Choi, JungBin Cha, SangMi Lee & Yoichiro Ogama. (2023) Pharmacokinetics and safety of CT-P17 (40 mg/0.4 ml) versus reference adalimumab: randomized study in healthy Japanese adults. Immunotherapy 15:3, pages 149-161.
Crossref
Crossref
Mohamed A. Kamal, John D. Davis, Pavel Kovalenko, Kamal Srinivasan, Eric L. Simpson, Takeshi Nakahara, Makoto Sugaya, Atsuyuki Igarashi, Marius Ardeleanu, Christine Xu & Kazuhiko Arima. (2022) Pharmacokinetics, pharmacodynamics, and exposure–efficacy of dupilumab in adults with atopic dermatitis. Clinical and Translational Science 15:10, pages 2342-2354.
Crossref
Crossref
Masaru Hirano, Masanori Yamada, Toshiaki Tanaka, Toshiko Koue, Tomohisa Saito, Mitsuo Higashimori, Hisao Ochiai, Junichi Yamamoto, Saori Yaguchi, Sachiko Mita & Katsutoshi Hara. (2021) Surveys/Research Exploring Japanese Phase I Studies in Global Drug Development: Are They Necessary Prior to Joining Global Clinical Trials?. Clinical Pharmacology in Drug Development 10:12, pages 1410-1418.
Crossref
Crossref
Hiroyuki Okamoto, Nathanael L. Dirks, Maria Rosario, Tetsuharu Hori & Toshifumi Hibi. (2021) Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease. Intestinal Research 19:1, pages 95-105.
Crossref
Crossref
Colby S. Shemesh, Phyllis Chan, Hui Shao, Derek-Zhen Xu, Daniel Combs, Shweta Vadhavkar, René Bruno & Benjamin Wu. (2021) Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region. Liver Cancer 10:5, pages 485-499.
Crossref
Crossref
Takafumi Ide, Amit Roy, Yasuhiko Imai & Heather E. Vezina. (2020) Model‐Based Determination of Elotuzumab Pharmacokinetics in Japanese Patients With Multiple Myeloma Incorporating Time‐Varying M Protein. The Journal of Clinical Pharmacology 61:1, pages 64-73.
Crossref
Crossref
Iris Rajman, Masaru Hirano, Wataru Honma & Sylvia Zhao. (2020) New paradigm for expediting drug development in Asia. Drug Discovery Today 25:3, pages 491-496.
Crossref
Crossref
Dandan Luo, Gautam Baheti, Michael A. Tortorici, Jutta Hofmann & Mikhail A. Rojavin. (2020) Pharmacometric Analysis of IgPro10 in Japanese and Non-Japanese Patients With Primary Immunodeficiency. Clinical Therapeutics 42:1, pages 196-209.e5.
Crossref
Crossref
Ken Ogasawara & G. Caleb Alexander. (2019) Use of Population Pharmacokinetic Analyses Among FDA‐Approved Biologics. Clinical Pharmacology in Drug Development 8:7, pages 914-921.
Crossref
Crossref
Fabrice HURBIN, Qiang LU, Marie T. BACCARA-DINET, Yoshiharu TAKAGI, Yoshihisa SHITARA, Seiko HORIUCHI, A. Thomas DiCIOCCIO, Masahiko KOBAYASHI & Aurélie BRUNET. (2019) Pharmacokinetics and Pharmacodynamics of Alirocumab, and Effects on PCSK9 and Low-Density Lipoprotein Cholesterol, in Japanese and Non-Japanese Patients. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 50:3, pages 73-80.
Crossref
Crossref
Chen Wang, Qingshan Zheng, Mingqiang Zhang & Hong Lu. (2018) Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of evolocumab between Caucasian and Asian populations. British Journal of Clinical Pharmacology 85:1, pages 114-125.
Crossref
Crossref
Daniel Xibille, Sandra Carrillo, Gabriela Huerta-Sil, Ramiro Hernández, Leonardo Limón, Guadalupe Olvera-Soto, Luis Javier Jara-Quezada, Abdieel Esquivel & Marcela Pérez-Rodríguez. (2018) Current State of Biosimilars in Mexico: The Position of the Mexican College of Rheumatology, 2016. Reumatología Clínica (English Edition) 14:3, pages 127-136.
Crossref
Crossref
Daniel Xibille, Sandra Carrillo, Gabriela Huerta-Sil, Ramiro Hernández, Leonardo Limón, Guadalupe Olvera-Soto, Luis Javier Jara-Quezada, Abdieel Esquivel & Marcela Pérez-Rodríguez. (2018) Escenario actual de los medicamentos biocomparables en México: posicionamiento del Colegio Mexicano de Reumatología, 2016. Reumatología Clínica 14:3, pages 127-136.
Crossref
Crossref
E Chigutsa, AJ Long & JE Wallin. (2017) Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients. CPT: Pharmacometrics & Systems Pharmacology 6:8, pages 560-568.
Crossref
Crossref
Chunze Li, Bei Wang, Dan Lu, Jin Y. Jin, Yuying Gao, Kiyoshi Matsunaga, Yuriko Igawa, Ihsan Nijem, Michael Lu, Alexander Strasak, Nataliya Chernyukhin & Sandhya Girish. (2016) Ethnic sensitivity assessment of the antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. Cancer Chemotherapy and Pharmacology 78:3, pages 547-558.
Crossref
Crossref
O. Nemoto, M. Furue, H. Nakagawa, M. Shiramoto, R. Hanada, S. Matsuki, S. Imayama, M. Kato, I. Hasebe, K. Taira, M. Yamamoto, R. Mihara, K. Kabashima, T. Ruzicka, J. Hanifin & Y. Kumagai. (2016) The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-co. British Journal of Dermatology 174:2, pages 296-304.
Crossref
Crossref